Pfizer to use Bayer compound to develop potential obesity, diabetes treatments

By Elaine Rigoli

Tampa, Fla., June 14 - Pfizer, Inc. and Bayer Pharmaceuticals Corp. have entered into an agreement granting Pfizer exclusive worldwide rights to Bayer's DGAT-1 inhibitors, a class of compounds that may modify lipid metabolism.

The lead compound in the class and currently in phase 1 development, BAY 74-4113 is a potential treatment for obesity, type 2 diabetes and other related disorders, the companies said in a news release.

Under the agreement, Bayer will receive an upfront fee, milestone payments and royalties on sales of any compounds successfully commercialized. Specific financial terms were not disclosed.

Pfizer, located in New York, discovers, develops, manufactures and markets prescription medicines in 11 therapeutic areas.

Based in Leverkusen, Germany, Bayer HealthCare, a subsidiary of Bayer AG, is a health care and medical products company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.